Pharma merger promises sweeping IP shake-up
In-house counsel at merging pharma businesses Wyeth and Pfizer face an uncertain future when the new entity looks to slash costs and increase efficiency. But, as WTR has discovered, the drugs companies have other problems to consider: from opportunistic counterfeiting to merging two very different IP teams.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the WTR experts.